Skip to main content
Premium Trial:

Request an Annual Quote

Glycotest, Oncimmune Explore Combining Technologies for Liver Cancer

NEW YORK (GenomeWeb) – NetScientific today announced that its portfolio firm Glycotest is collaborating with Oncimmune to investigate combining their technologies for the early detection of liver cancer.

Glycotest and Oncimmune will jointly clinically validate their combined tests, which could then be co-developed.

Oncimmune is contributing its autoantibody-based lung cancer test, EarlyCDT-Lung, to the collaboration. The Rockville, Md.-based biotech firm is expanding the technology to detect liver cancer and other solid tumor cancers. Glycotest, a spinout of Drexel University College of Medicine and Baruch S. Blumberg Institute, is developing proprietary glycoprotein biomarkers and assay technology for liver diseases, including liver cancer.

"We believe that the most clinically valid and cost-effective way to address the early detection of cancer is via two routes, through the further development of our proprietary autoantibody technology and its combination with other complementary technologies," Oncimmune CEO Geoffrey Hamilton-Fairley said in a statement.

Financial and other terms of the agreement were not disclosed.

NetScientific is a biomedical and healthcare technology group that funds and develops technologies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.